Transgenic mice expressing a growth hormone receptor antagonist (GHA) — engineered via a glycine-to-lysine mutation at position 120 of human GH — lived significantly longer than controls. Median and maximal lifespan increased in both sexes, with females gaining up to 265 additional days at maximum lifespan (p = 9×10⁻⁶). At two years of age, GHA mice showed reduced frailty and enhanced grip strength despite greater adiposity, suggesting GH antagonism decouples metabolic fat accumulation from functional decline.
This finding carries substantial weight in the longevity field. GH-IGF-1 axis suppression has long been associated with extended lifespan — from Ames and Snell dwarf mice to C. elegans daf-2 mutants — but those models involve congenital GH deficiency from birth. GHA mice, by contrast, block GH receptor signaling post-developmentally, making this mechanistically closer to a pharmacological intervention. Crucially, the FDA-approved drug Pegvisomant (Somavert) operates on this exact principle in humans, treating acromegaly by blocking GH receptor binding. That a clinically available agent shares the core mechanism of this lifespan extension is paradigm-shifting for translational medicine.
Limitations are real: this is an animal study with a single transgenic line, and the metabolic trade-off of increased adiposity warrants scrutiny. Whether equivalent GH antagonism in adult humans — absent the lifelong transgene expression — would replicate these effects remains untested. Still, this is among the most translationally compelling longevity findings in years.